Pathogenetic significance of the use of a humanized monoclonal antibody to the IL-6-α receptor (tocilizumab) in the treatment of immuno-inflammatory diseases

Pathogenetic significance of the use of a humanized monoclonal antibody to the IL-6-α receptor (tocilizumab) in the treatment of immuno-inflammatory diseases

The article discusses the participation of interleukin-6 (IL6) in the formation of pathogenetic mechanisms of immuno-inflammatory diseases (IID). IL6 is one of the central cytokine in progressive IID. The biological activity of IL6 is determined by its ability to activate target genes that regulate...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, I. B. Belyaeva, R. R. Samigullina, A. L. Chudinov, A. M. Dadalova
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-07-01
Series:Медицинский совет
Subjects:
immuno-inflammatory diseases
rheumatoid arthritis
systemic lupus erythematosus
systemic scleroderma
systemic vasculitis
genetic engineering biological therapy
il6α receptor blockers
tocilizumab
covid-19
Online Access:https://www.med-sovet.pro/jour/article/view/5687

Similar Items

Similar Items